Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARSKIN: Pembrolizumab in Unresectable Squamous Cell Carcinoma of the Skin
NCT02883556Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2017
- Primary completion
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in squamous cell carcinoma of the skin (SCC), sponsored by Assistance publique - Hôpitaux de Paris. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the skin (SCC)
Beyond the preview
Go deeper on NCT02883556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02883556.